This review provides an update on the treatment of benign prostatic hyperplasia and the pharmacologic considerations for perioperative care. By age 85 years, approximately 90% of men have prostate histologic characteristics consistent with benign prostatic hyperplasia. Pharmacologic treatment with an alpha 1 receptor antagonist may reduce symptoms and, when given in combination with a 5-alpha-reductase inhibitor, may decrease the risk of urinary retention and the need for surgical intervention. Transurethral resection of the prostate has been the historical standard when surgical intervention is indicated. However, recent evidence suggests that Holmium laser enucleation of the prostate may have similar efficacy with less risk of complications and with decreased catheterization time. Prostatic urological operations may have perioperative complications, including urethral bleeding, acute urinary retention, urinary tract infection, urge incontinence, and venous thromboembolism. Pharmacist recommendations for the appropriate use of laxatives, antibiotics, anticoagulation, and urinary antispasmodics are key components of perioperative management. Surgical interventions improve symptoms but may have complications, providing the pharmacist an opportunity to improve perioperative care.
Introduction
Approximately 50% of men have prostate histologic characteristics consistent with benign prostatic hyperplasia (BPH) by age 60 years. 1 At age 85 years, their percentage increases to 90%. More than 14 million men in the United States currently have some type of lower urinary tract symptoms (LUTS), and most have these symptoms secondary to BPH. 2 This prostate disorder is characterized by overgrowth of prostate tissue, urethral lumen narrowing, and subsequent blockage of urine flow. Although not usually life threatening, LUTS have a substantial impact on a patient's quality of life and must be managed appropriately. Active surveillance, pharmacologic therapy, and surgical intervention are all used to treat and prevent the progression of BPH. 3 Historically, transurethral resection of the prostate (TURP) has been the reference surgical procedure for most patients who have moderate to severe LUTS and in whom pharmacologic therapy has failed. Emerging surgical therapies involving laser technology have shown comparable efficacy to TURP. Prevention and identification of surgical complications, which occur most frequently in the perioperative and late postoperative phases, 4 require great vigilance from the surgical pharmacist to provide optimal outcomes for this patient population.
Pathophysiology of BPH
The exact cause of BPH remains unclear. However, investigators have proposed that LUTS have both a static and a dynamic source. 3 A proliferative mechanism on the tissue causes the gland to grow in size, creating urethral blockage as the prostate pushes against the urethra. Concurrently, an increase in prostatic smooth muscle tone creates troublesome resistance within the enlarged gland by diminishing urethral lumen diameter. Combating the static component of prostatic growth requires early intervention and serves primarily to prevent disease progression. Decreasing smooth muscle tone also appears to have treatment value, primarily in symptom relief. 5 Over time, the static element of BPH (prostate growth) is driven by the conversion of testosterone into dihydrotestosterone by the enzyme 5-alpha-reductase. The pathophysiology of dihydrotestosterone hinges on its ability to stimulate prostatic tissue growth. 6 When the prostate size increases, a mechanical blockage produces resistance within the urethra. If no intervention takes place, increased resistance to urinary flow may resolve, stabilize, or progress to bladder outlet obstruction (BOO). 3 When 5-alpha-reductase can be inhibited effectively, serum dihydrotestosterone levels decline and may result in decreased prostate gland size over time. 7 Clinically, low dihydrotestosterone levels do not necessarily result in symptom relief.
The dynamic component in BPH-smooth muscle tone-is increased through excessive stimulation of the alpha 1 -adrenergic receptors, which are abundant in the prostatic capsule, bladder neck, and proximal urethra. Blocking these receptors allows nonvascular, smooth muscle relaxation in these areas, followed by a decrease in bladder pressure. As demand on the detrusor muscle to force urine through the obstructed passage decreases, normalization of bladder function may be possible. 8 The consequences of untreated BOO include hydronephrosis, renal insufficiency, urinary retention, recurrent infection, and bladder decompensation. 9, 10 
Diagnostics and Patient Symptoms
According to the 2011 update of the American Urological Association (AUA) guidelines on the management of BPH, several diagnostic tests are recommended to guide LUTS management and the diagnosis of BPH. 3 These tests include digital rectal examination, voiding frequency/volume report, urinalysis, and measurement of serum prostate-specific antigen. Table 1 contains a list of common patient symptoms consistent with BPH. To standardize the evaluation of LUTS and to aid in BPH severity categorization, the AUA developed its Symptom Index. To complete this assessment tool, the severity of 7 specific symptoms is rated on a scale of 1 to 5. A particular patient's LUTS are considered mild for a total score of 2 to 7, moderate for 8 to 19, and severe for 20 to 35. 3 Patients who have evidence of upper urinary tract injury presenting with renal insufficiency, gross hematuria, or bladder stones generally become candidates for surgical intervention. Surgery is also indicated for those with recurrent urinary tract infections or LUTS that do not respond adequately to other therapies. Surgical intervention may be considered early in symptomatic BPH, but the patient should be informed of the risks and benefits associated with the different treatment methods. 3 
Pharmacologic Therapy Overview
Pharmacologic strategies generally antagonize the 2 established components of urethral narrowing secondary to BPH. The dynamic component of BPH is the overstimulation of prostatic smooth muscle, which results in contraction of the prostate around the urethral lumen. The static component of this disease is directly related to the excessive growth of prostatic tissue into the urethral space. An alpha-adrenergic blocker (alpha-blocker) may relax prostatic smooth muscle and alleviate symptoms. Alpha-blockers are typically associated with various adverse effects, including hypotension (less selective agents), dizziness, headache, abnormal ejaculation, fatigue, and rhinitis. Postural hypotension, orthostatic hypotension, and orthostasis are terms used to describe the clinically important blood pressure lowering associated with some alpha-blockers when standing up, most notably terazosin hydrochloride. 8 Use of a 5-alphareductase inhibitor (5-ARI) may provide benefit by depleting dihydrotestosterone, a hormone that facilitates prostate tissue growth. 11 The 5-ARIs have a relatively benign adverse effect profile, with impotence, abnormal ejaculation, and reduced libido occurring in approximately 4% to 8% of patients. 12, 13 Patients who are not bothered by LUTS or have an AUA Symptom Index score of less than 8 may use the strategy of watchful waiting as initial management. For those with moderate to severe LUTS secondary to BPH, initial therapy with an alpha-blocker is usually appropriate. Alfuzosin hydrochloride, doxazosin mesylate, tamsulosin hydrochloride, and terazosin hydrochloride are alpha-blockers with equal clinical effectiveness, but they differ in adverse effect profiles.
Alpha-Blockers
Prazosin was the first selective alpha 1 -blocker investigated for the treatment of BPH. 8 However, prazosin is not widely used for LUTS/BPH treatment due to multiple daily dosing and adverse effects related to its blood pressure-lowering properties. 3, 8 Long-acting alpha 1 -blockers, such as doxazosin and terazosin, have generic equivalents and may be reasonable, less costly choices in therapy. 3 Doxazosin and terazosin are indicated for BPH, as well as hypertension, and are generally taken once daily. Efficacy in the treatment of hypertension is due to their indiscriminate action at both the alpha 1a (nonvascular smooth muscle) and the alpha 1b (vascular smooth muscle) receptors. In addition to relaxing stromal smooth muscle of the prostate, alpha 1a/b -blockers also cause relaxation in vascular smooth muscle and a subsequent lowering of blood pressure. Syncope and ''first-dose'' hypotension may occur with these agents, especially in the elderly population. Patients and heath care professionals should note the increased fall risk associated with the first several days of therapy. Therefore, gradual dosage titration, bedtime dosing, and blood pressure monitoring are warranted with these medications. 14, 15 Newer alpha 1 -blockers, such as alfuzosin, tamsulosin, and silodosin, have greater selectivity for alpha 1a -adrenergic receptors and are not generally associated with the first-dose effect. However, nocturia may be problematic for some patients and thus require an earlier administration time. These agents were more costly until generic tamsulosin became available in 2010. The 2011 average wholesale price for tamsulosin was approximately $0.25/dose, making it the least expensive single agent for pharmacologic management of BPH. 16 Table 2 provides additional information about the various pharmacologic therapies for BPH. 12-21
5-Alpha-Reductase Inhibitors
Two 5-ARIs are currently indicated by the US Food and Drug Administration (FDA) for BPH. These agents are not known for symptom control but rather for decreased risk of acute urinary retention (AUR) and of the need for prostate-related surgery. 3 Although no efficacy data are available for direct comparison, 2 pharmacologic parameters differentiate these agents. Dutasteride inhibits both the type I and type II isoenzymes of 5-alpha-reductase, whereas finasteride inhibits the type II isoenzyme alone. The type II isoenzyme is found primarily in the prostate and reproductive tissues; the type I isoenzymes are found in the prostate, liver, and skin. This effectiveness may translate into a greater reduction of dihydrotestosterone from dutasteride therapy, but the clinical impact continues to be uncertain. In 43 men with BPH, 3 months of treatment with dutasteride at a dose of 0.5 mg daily resulted in a 94% decrease in serum dihydrotestosterone from baseline. 22 Conversely, 1 week of finasteride treatment in 63 men with symptomatic BPH at various finasteride doses (between 1 and 100 mg daily) showed a 70% decline in serum dihydrotestosterone. 21 In addition, the half-life of dutasteride is 5 weeks, compared with the 6-to 8-hour half-life of finasteride. 12, 13 Prescribers for patients who have difficulty with treatment adherence may consider dutasteride in the treatment armamentarium, whereas prescribers for patients who have persistent adverse effects may use this pharmacokinetic parameter to promote the use of finasteride. 3 We must note that the clinical significance of half-life differences for these agents has not been well investigated. In addition, the onset of action for 5-ARIs is much slower than for the alpha-blockers. It may take as much as 3 months of dutasteride therapy or 6 months of finasteride treatment to observe clinical effect, and no dosage titration is required for 5-ARIs because of a relatively mild adverseeffect profile and a wide therapeutic index. We emphasize that neither finasteride nor dutasteride should be administered to a woman or a child because of potential teratogenic effects. Women should use protective gloves when handling or administering 5-ARI medications. 12, 13 Combination Therapy
Combination therapy with an alpha-blocker and a 5-ARI has shown benefit in men at high risk for disease progression. 12 Proscar, 13 Cardura, 14 Hytrin, 15 Uroxatral, 17 Candidates for combination therapy typically are patients who have symptomatic BPH. The alpha-blocker may decrease LUTSs as the 5-ARI decreases prostate size over time. 23, 24 The decision to use monotherapy versus combination therapy must be a collaborative decision between the patient and the prescriber, weighing symptomatic control against the possibility of additional adverse effects.
Anticholinergics
Anticholinergic agents may be considered as treatment alternatives or adjuncts in the management of predominantly irritative LUTS/BPH. Anticholinergics used in BPH exert antimuscarinic effects on the detrusor muscle of the bladder. Relaxation of the detrusor muscle leads to decreased bladder overactivity and may alleviate LUTS. 25 The 2011 update to the AUA guidelines recommends attaining a baseline post void residual (PVR) before initiating anticholinergics, using caution in patients with a PVR greater than 250 to 300 mL who may be at risk for AUR. Randomized clinical trial evidence, which has primarily evaluated the use of tolterodine tartrate in combination with alphablocker therapy, has not sufficiently demonstrated efficacy. However, benefit for some patients may exist. 3 Athanasopoulos et al 26 randomized 50 consecutive subjects with BOO and overactive bladder (OAB) to either tamsulosin hydrochloride 0.4 mg orally daily or the combination of tamsulosin plus tolterodine tartrate immediate-release 2 mg orally twice a day. At 3 months, the combination group demonstrated a statistically significant improvement in quality-of-life scores with no reported episodes of AUR. 26 Kaplan et al 25 randomly assigned 879 subjects with BPH and OAB to 1 of 4 groups: placebo, tolterodine tartrate extended-release 4 mg orally once a day, 0.4 mg tamsulosin hydrochloride orally once a day, or the combination of tolterodine plus tamsulosin for 12 weeks. At week 12, a significantly greater proportion of patients in the combination group reported treatment benefit over the 3 other groups. Changes in PVR, maximum urinary flow rate, and incidence of AUR did not differ significantly between groups. 25 Indeed, the trials summarized above indicate the actual risk of AUR with tolterodine tartrate may be exaggerated. Despite the potential benefit of anticholineric medications in BPH, adverse effects including dizziness, dry mouth, constipation, and AUR may be problematic and should be carefully monitored. Discussing the risks associated with anticholinergic therapy, particularly in elderly persons, is also important.
Complementary and Alternative Medicine
Saw palmetto (Serenoa repens) and stinging nettle (Urtica dioica) are 2 dietary supplements which have been used as nonconventional therapy for LUTS/BPH. The 2011 update to the AUA guidelines does not currently recommend the use of any dietary supplement for BPH treatment. 3 Unless higher quality evidence becomes available, the use of dietary supplements or other phytotherapeutic agents for LUTS/BPH should not be advocated.
Surgical Options
Surgery is generally indicated for men with symptomatic BPH or prostate cancer who have urinary tract injury ( Table 3 ). The 2011 update to the AUA guidelines suggests that some patients may appropriately consider surgical intervention sooner, depending on the clinical picture. 3 Urinary tract injury may present in various renal and urinary dilemmas. 3 Historically, TURP has been the surgical mainstay of symptomatic BPH treatment. However, the limitations of potential postoperative morbidities, indwelling catheter time, and hospital length of stay have threatened the contemporary status of TURP. 27 During this procedure, a resectoscope and diathermy loop are introduced into the bladder through the penis. The prostate adenoma is then resected in strips and dropped into the bladder. After the capsule of the prostate is exposed, the strips are evacuated from the bladder with an irrigation solution. Hemostasis is restored using electrocautery, and a new epithelial surface develops during 6 to 12 weeks. TURP is indicated only for a prostate size less than 100 g. Open prostatectomy used to be the only reasonable option for men with a larger prostate. However, patients now have more options in the surgical management of BPH. 28 New surgical therapies for BPH have emerged in the past decade. Most of these procedures involve laser technology and have been labeled collectively minimally invasive surgical therapies (MISTs). These therapies have claimed advantages over TURP and open prostatectomy, but evidence to support their use over long-standing surgical treatments has been lacking until recently. A meta-analysis by Ahyai and colleagues 4 in 2010 found that Holmium laser enucleation of the prostate (HoLEP), first introduced in 1992, is the only endoscopic procedure to date with proven superior efficacy to TURP. The HoLEP procedure is prostate size independent and may be used to remove prostates that were able to be removed only with open prostatectomy before its development. 4 Holmium laser ablation of the prostate is a similar procedure, but it is designed for a prostate of less than 60g.
HoLEP involves the insertion of a resectoscope into the penile urethra, visualization of anatomy, and laser enucleation of each prostatic lobe. Individually, each lobe is enucleated, dissected, separated, and inspected before being dropped into the bladder. The laser fiber and stabilizing catheter are removed, and a morcellator is inserted. This device decreases the enucleate size (through a cutting mechanism) as it vacuums the tissue out of the bladder. Hemostasis is accomplished simultaneously during laser enucleation. 29 
Surgical Complications
Ahyai and colleagues 4 evaluated functional outcomes and complications associated with TURP and several of the most common MISTs. Twenty-three controlled trials, including more than 2245 patients randomly assigned between 1997 and 2009, were evaluated. 4 For the scope of the present article, we use the findings for TURP and HoLEP.
Surgical complications may be classified into 3 categories: intraoperative, perioperative, and late. The most common intraoperative complication in TURP procedures is bleeding requiring transfusions, occurring in 2% of cases. In 0.8% of TURP procedures, patients have a dilutional hyponatremia due to systemic absorption of the glycine irrigant used for the procedure. This condition is called transurethral resection syndrome (TUR syndrome) and may carry substantial clinical consequences if not managed appropriately.
Nausea is typically the first symptom of hyponatremia secondary to TUR syndrome. However, as cerebral edema becomes a concern, neurologic symptoms, including confusion, twitching, seizures, hypotension, and transient visual disturbances, may develop and require intervention. Hypertonic saline, hemodialysis, and loop diuretics have all been used in the clinical management of TUR syndrome. 4, 30 Perioperative complications are more frequent. AUR, clot retention, and urinary tract infection occur in about 4% to 5% of patients who undergo TURP. Life-threatening, late complications are rare after TURP. However, retrograde ejaculation may occur in up to 76% of patients at 6 months. 29 Other late complications to note include bladder neck stricture (2%), urethral stricture (4%), and urgency (2.2%). 4 Complications from HoLEP procedures are similar to TURP, with a few exceptions. Bladder injury may affect approximately 3% of patients because of accidental manipulation of the morcellator during tissue evacuation, a complication not observed with TURP. TUR syndrome is not associated with HoLEP because of the use of a normal saline irrigant. Lateoccurring urgency (5.6%) and transient dysuria (1.2%) may be more frequent than in TURP. However, the percentages given in the analysis by Ahyai and colleagues 4 were not compared for statistical significance. Mean urinary catheter time post-HoLEP is about 24 hours-a marked decrease from the post-TURP average of almost 3 days. 4
Perioperative Anticoagulation and Prophylaxis for Venous Thromboembolism
Some debate surrounds the perioperative use of warfarin sodium and low-molecular-weight heparin (LMWH) in urological surgery. Although some specific recommendations were made for this patient population by Meyer and colleagues 31 in 2003, the 2012 American College of Chest Physicians (ACCP) guidelines 32 provide perioperative anticoagulation strategy in common surgical scenarios. The clinician should attempt to separate patients into risk strata for both bleeding and thromboembolism. Although a validated tool for bleeding risk stratification is lacking, urologic procedures involving prostate resection are considered ''high risk'' for bleeding in the setting of anticoagulant and antiplatelet drug use. Therefore, the clinical pharmacist should assess bleeding risk using the perioperative anticoagulant or antiplatelet properties and its proximity to surgery. A tool for stratifying thromboembolic risk is provided in the 2012 ACCP guidelines. Therefore, patients are typically characterized as low, intermediate, or high risk of thrombosis. 32 Patients who are at low risk for venous thromboembolism (VTE; eg, VTE >3 months ago, atrial fibrillation with no stroke history) should stop warfarin approximately 5 days before surgery and allow their international normalized ratio to reach a normal value. These patients may then resume warfarin therapy at 12 to 24 hours postoperatively. Those patients who have an intermediate risk of VTE (eg, VTE 1 to 3 months ago, history of aortic valve placement) may stop warfarin treatment approximately 5 days before surgery and initiate LMWH therapy 2 days before the procedure as the international normalized ratio returns to normal. Although Meyer and colleagues 31 recommend giving the last dose of LMWH at 12 hours before urologic surgery, the 2012 ACCP guidelines 32 for perioperative management of anticoagulation suggests withholding the last dose of LMWH before surgery when a twice-daily regimen is used. Administering half of the daily dose of LMWH the morning before surgery is recommended for patients using a oncedaily regimen. 32 TURP and other MISTs carry a high risk of postprocedure bleeding. However, warfarin therapy may be resumed when hemostasis is established, or generally the evening of surgery. For the majority of patients, the full effect of warfarin anticoagulation does not occur until 3 to 5 days of therapy. When bridging is required, administering the first dose of LMWH during a warfarin bridging protocol at 48 to 72 hours postprocedure is recommended for these patients after hemostasis is secured. For patients with high risk of VTE (eg, patients with mitral valve, stroke history, multiple risk factors, or VTE in the past month), an intravenous infusion of unfractionated heparin may be titrated to full anticoagulation (activated partial thromboplastin time ratio, 1.5-2.5), discontinued 6 hours before surgery, and recommenced 12 hours postoperatively if hemostasis has been established. For high-risk patients, warfarin bridging with either unfractionated heparin or LMWH is recommended. 31, 32 Perioperative oral anticoagulation may not be discontinued in all patients with urologic surgery. 33 However, this medical situation is rarely encountered in clinical practice.
Most transurethral operations, including TURP, require only early ambulation for VTE prophylaxis when completed in the outpatient setting. Intermittent pneumatic compression and graduated compression stockings are acceptable methods of VTE prevention for hospitalized patients and those with increased risk. Advanced age (>40 years), active malignancy, prior VTE, trauma, immobility, major surgery, and blood disorders are risk factors for perioperative VTE in urological surgery. Many, additional risk factors for VTE are not addressed in this article. Depending on the clinical picture, low-dose unfractionated heparin or LMWH may be indicated when high-risk patient parameters are met. 32, 34 
Implications for Pharmacologic Management and Perioperative Care
Medications used in the treatment of BPH have notable adverse effects and monitoring parameters that require vigilance from the clinical pharmacist on the surgical floor. Perioperative and late complications consistently occur more often than intraoperative complications for TURP, HoLEP, and other MISTs, but these events may be prevented and managed with appropriate nursing care, careful monitoring, and drug therapy. The perioperative setting continues to present a need for the pharmacist's vital role in optimizing outcomes for patients. 
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